Clinical trial NCT00610311 (phase 2, status: terminated)
Conditions: metastatic melanoma, skin cancer
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C79.2, C44.500, C44.90, D23.9, D48.5, C44.00, C44.301
Drugs: cyclophosphamide, fludarabine phosphate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    the study was terminated due to low accrual.
  
Eligibility criteria:

        -INCLUSION CRITERIA:

          1. Metastatic melanoma with measurable disease.

          2. Previously received high dose interleukin-2 (IL-2) and have been either non-responders
             (progressive disease) or have recurred.

          3. Positive for gp100 by immunohistochemistry (IHC) which will be reviewed by the
             Laboratory of Pathology at National Cancer Institute (NCI).

          4. Tumor infiltrating lymphocyte (TIL) cells not available for treatment on other Surgery
             Branch protocols.

          5. Greater than or equal to 18 years of age.

          6. Willing to sign a durable power of attorney.

          7. Able to understand and sign the Informed Consent Document.

          8. Clinical performance status of Eastern Oncology Oncology Group (ECOG) 0 or 1.

          9. Life expectancy of greater than three months.

         10. Patients of both genders must be willing to practice birth control for four months
             after receiving the preparative regimen.

         11. Must be human leukocyte antigens (HLA-A) 0201 positive.

         12. Serology:

               -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
                  treatment being evaluated in this protocol-depends on an intact immune system.
                  Patients who are HIV seropositive can have decreased immune -competence and thus
                  be less responsive to the experimental treatment and more susceptible to its
                  toxicities.)

               -  Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen
                  negative.

         13. Hematology:

               -  Absolute neutrophil count greater than 1000/mm^3.

               -  White blood cell (WBC) (greater than 3000/mm^3).

               -  Platelet count greater than 100,000/mm^3.

               -  Hemoglobin greater than 8.0 g/dl.

         14. Chemistry

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than
                  or equal to 2.5 times the upper limit of normal.

               -  Serum creatinine less than or equal to 1.6 mg/dl.

               -  Total bilirubin less than or equal to 2.0 mg/dl, except in patients with
                  Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

         15. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus.

         16. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients' toxicities must have
             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).

         17. Six weeks must have elapsed since prior MDX-010 therapy to allow antibody levels to
             decline, and patients who have previously received MDX-010 or ticilimumab must have a
             normal colonoscopy with normal colonic biopsies.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

          2. Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          4. Ongoing opportunistic infections (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. History of coronary revascularization.

          8. Documented left ventricular ejection fraction (LVEF) of less than 45 percent in
             patients with:

               -  Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, 2 degree or 3 degree
                  heart block.

               -  Age greater than or equal to 60 years old.

          9. Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60
             percent predicted for patients with:

               -  A prolonged history of cigarette smoking (greater than 20 pack/year within the
                  past 2 years).

               -  Symptoms of respiratory distress.